Get More Information on Antimicrobial Resistance Surveillance Market - Request Sample Report
The Antimicrobial Resistance Surveillance Market was valued at USD 5.90 Billion in 2023 and is projected to grow to USD 9.50 billion by 2032 with a CAGR of 5.47% over the forecast period 2024-2032.
Antimicrobial resistance (AMR) is a growing public health crisis, with pathogens like bacteria and fungi developing mechanisms to evade the effects of life-saving drugs. This is where antimicrobial resistance surveillance comes in – it's the continuous monitoring of these microbial populations to understand how resistance patterns are evolving.
Globally, AMR is responsible for an estimated 700,000 deaths annually. This highlights the severity of the threat. Surveillance programs like the ATLAS platform, which recently in April 2020 expanded to include antifungal data alongside its existing bacterial data, play a vital role.
ATLAS, with its access to data from over 15,500 fungal isolates across 40 countries, offers a unique window into global resistance trends. This real-world data, updated yearly, empowers decision-makers like doctors and public health officials. By analyzing these trends, they can adapt treatment strategies, implement stricter antibiotic stewardship programs, and refine infection control measures. This ultimately helps to stay ahead of the curve in the fight against AMR.
A prime example of global antimicrobial resistance surveillance is the WHO's GLASS program. Launched in 2015, it tracks resistance patterns in bacteria responsible for common infections. GLASS has since expanded to cover antifungal resistance and antibiotic consumption data, promoting a "One Health" approach that considers animal and human health as interconnected. With participation from over 127 countries by late 2022, GLASS provides crucial data for informed strategies to combat the growing threat of AMR.
The National Antimicrobial Resistance Monitoring System (NARMS) stands as an example of a successful antimicrobial resistance surveillance program. Established in 1996, NARMS is a collaborative effort between various US agencies, including the CDC, FDA, USDA, and state public health departments. Furthermore, NARMS data plays a crucial role in the FDA's regulatory decisions regarding antibiotics. By understanding resistance trends, the FDA can make informed choices to preserve the effectiveness of these life-saving drugs for both humans and animals.
Antimicrobial resistance (AMR) stands as a stark example of a global health threat with far-reaching consequences. In 2019 alone, it's estimated to have been responsible for a staggering 4.95 million deaths. This grim statistic underscores the urgency of addressing this issue. The potential future impact of AMR paints an even more alarming picture. If left unchecked, it's projected to claim up to 10 million lives annually by 2050. Beyond the human cost, AMR poses a significant economic challenge, with estimates suggesting a potential reduction in global GDP by 1.1% to 3.8% by the same year. This example highlights the multifaceted challenge of AMR. It's not just a healthcare concern; it has the potential to cripple economies and devastate societies worldwide. The disproportionate impact on low- and middle-income countries further complicates the issue, demanding a global, coordinated response to effectively combat this growing threat.
Drivers
Burgeoning Burden of Antibiotic-Resistant Infections
Antibiotic resistance has become a critical public health concern. A Pew Charitable Trusts article from July 2023 paints a grim picture that is in the US alone, over 2.8 million antibiotic-resistant bacterial infections occur annually, leading to more than 35,000 deaths. This alarming trend is mirrored globally, with the World Health Organization (WHO) identifying antibiotic-resistant bacteria as a major threat.
Desperate Need for New Therapies
The diminishing effectiveness of existing antibiotics necessitates the development of novel treatment options. A beacon of hope emerged in a recent Science Daily article in July 2023 highlighting a groundbreaking discovery by Adela Melcrova. Her research revealed a new antibiotic, AMC-109, that works through a unique mechanism, offering promise for overcoming existing resistance patterns and paving the way for future drug development. The WHO, recognizing this critical need, collaborated with the Global AMR R&D Hub to present a report to G7 finance in May 2023. This report emphasizes progress in encouraging the development of new antibacterial treatments, highlighting the importance of a "One Health" approach that considers the interconnectedness of human and animal health.
Heightened Public Health Awareness and Economic Concerns
The global rise of antibiotic resistance has significant economic consequences. A WHO article from November 2023 underscores this point, revealing the impact on international trade, healthcare costs, and overall productivity. Furthermore, the WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS) report in November 2023 sheds light on the alarming resistance rates observed in common bacterial pathogens. The report highlights concerning statistics, such as a median rate of 42% for third-generation cephalosporin-resistant E. coli and 35% for methicillin-resistant Staphylococcus aureus across 76 countries. Additionally, the report reveals a disturbing trend – in 2020, 1 in 5 urinary tract infections caused by E. coli exhibited reduced susceptibility to standard antibiotics. This growing public health concern and economic strain are driving the demand for effective surveillance solutions.
Collaborative Efforts for Novel Treatment Methods:
Researchers and pharmaceutical companies are joining forces to combat the challenge of antibiotic resistance. A recent example is the collaboration between Karolinska Institute and Therakind in November 2023. This partnership aims to discover innate molecules within the human body that possess potent antimicrobial properties, specifically targeting infections caused by antibiotic-resistant bacteria, particularly those affecting the brain. This innovative approach highlights the growing focus on finding alternative solutions to combat these "superbugs."
In conclusion, the antimicrobial resistance surveillance market is being propelled by the alarming rise of antibiotic-resistant infections, the urgent need for new treatment options, heightened public health awareness, and collaborative efforts to discover novel therapeutic strategies. As the fight against superbugs intensifies, the market for surveillance solutions will continue to flourish.
Restraints
The High Cost of AMR Diagnostic Systems
The high cost of AMR diagnostic systems acts as a significant barrier to wider adoption, particularly in resource-limited settings. Addressing this cost issue is crucial for ensuring more widespread access to these essential tools and ultimately achieving better control over the growing threat of antimicrobial resistance.
Automated systems, while offering advantages, come at a hefty price tag. According to NorthShore University Health System, the annual cost of reagents for an automated system processing 29,200 tests is a staggering USD 165,856. This is a stark contrast to the USD 43,508 spent annually on reagents for the disk diffusion method, a more traditional approach.
Key Market Segmentation
By Solution
The tools used to track antimicrobial resistance fall into different categories, but one dominated: diagnostic kits. In 2023, this segment held the biggest slice of the antimicrobial resistance surveillance market with 46%. This dominance is driven by the growing need for fast and reliable ways to identify resistant bacteria. These kits are the workhorses in labs, analyzing patient samples like blood, urine, and respiratory secretions to detect the presence of such resistant bacteria.
Need any customization research on Antimicrobial Resistance Surveillance Market - Enquiry Now
By Application
Clinical diagnostics led the pack with 44% in 2023, and this segment is projected for continued growth. The rise in antibiotic-resistant infections is a key driver, as doctors need faster, more precise tools to guide treatment. These diagnostic solutions determine a bacteria's susceptibility to different drugs, empowering healthcare providers to make informed decisions and improve patient outcomes.
By End User
Hospitals and clinics were the battleground for antimicrobial resistance, make them the unsurprised leader in this market segment with 56% share in 2023. They account for the biggest slice of the pie due to two key factors. Firstly, these facilities are on the frontlines, witnessing and treating the most cases of resistant infections. Secondly, hospitals and clinics are often mandated to conduct surveillance themselves, actively monitoring resistance trends within their walls.
Regional Analysis
North America held the top spot, with a dominated 37% market share in 2023. This lead can be attributed to their strong emphasis on research and development. Here, substantial funding fuels scientific breakthroughs, technological advancements, and the creation of innovative antibiotic therapies.
However, the fastest growth is expected to surge from the Asia Pacific region. Here, governments are taking a proactive stance by developing and implementing national action plans. China's recently launched plan (2022-2025) exemplifies this commitment. These plans often go beyond traditional methods, incorporating areas like vaccination, tackling AMR in the environment, and fostering collaboration across different sectors. This proactive approach by regional governments in Asia Pacific is poised to significantly shape the future of the global market.
Danaher, Bioanalyse, Luminex Corporation, Alifax S.r.l., Thermo Fisher Scientific, Wolters Kluwer N.V., Lumed, BioSpace, Roche Diagnostics, OpGen, Inc., Cepheid, Abbott Laboratories, Accelerate Diagnostics, Inc., Qiagen, Liofilchem S.r.l., Bio-Rad, Becton, Merck KgaA, Dickinson and Company, Bruker, Biomerieux, and others.
Recent Developments
In a recent advancement to combat antimicrobial resistance (AMR), the Food and Agriculture Organization (FAO) launched a global information system called InFARM. This ambitious program aims to strengthen national surveillance systems for tracking AMR in animals and food products. InFARM facilitates the collection of reliable and timely data at national, regional, and global levels. To jumpstart this initiative, FAO is calling on its member countries to participate in the first-ever InFARM annual data collection effort in 2024.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 5.90 billion |
| Market Size by 2032 | US$ 9.50 Billion |
| CAGR | CAGR of 5.47% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Solution (Diagnostic kits, Diagnostic systems, Surveillance software, Services) • By Application (Clinical Diagnostics, Public Health Surveillance, Other Applications) • By End User (Hospitals & Clinics, Research & Academic Institutes, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Danaher, Bioanalyse, Luminex Corporation, Alifax S.r.l., Thermo Fisher Scientific, Wolters Kluwer N.V., Lumed, BioSpace, Roche Diagnostics, OpGen, Inc., Cepheid, Abbott Laboratories, Accelerate Diagnostics, Inc., Qiagen, Liofilchem S.r.l., Bio-Rad, Becton, Merck KgaA, Dickinson and Company, Bruker, Biomerieux, and others. |
| Key Drivers | • Burgeoning Burden of Antibiotic-Resistant Infections •Desperate Need for New Therapies •Heightened Public Health Awareness and Economic Concerns •Collaborative Efforts for Novel Treatment Methods |
| RESTRAINTS | • The High Cost of AMR Diagnostic Systems |
Ans: The estimated compound annual growth rate is 5.47% during the forecast period for the Antimicrobial Resistance Surveillance market.
Ans: The projected market value of the Antimicrobial Resistance Surveillance market is estimated USD 5.90 billion in 2023 and expected to reach USD 9.50 billion by 2032.
Ans: Burgeoning burden of antibiotic-resistant infections is one of the drivers of the Antimicrobial Resistance Surveillance market.
Ans: The high cost of AMR diagnostic systems hampers the market growth which is one of the restraints of the Antimicrobial Resistance Surveillance market.
Ans: North America is the dominating region with 37% market share in the Antimicrobial Resistance Surveillance market.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Industry Flowchart
3. Research Methodology
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
5. Porter’s 5 Forces Model
6. Pest Analysis
7. Antimicrobial Resistance Surveillance Market Segmentation, by Solution
7.1 Introduction
7.2 Diagnostic kits
7.3 Diagnostic systems
7.4 Surveillance software
7.5 Services
8. Antimicrobial Resistance Surveillance Market Segmentation, by Application
8.1 Introduction
8.2 Clinical Diagnostics
8.3 Public Health Surveillance
8.4 Other Applications
9. Antimicrobial Resistance Surveillance Market Segmentation, by End User
9.1 Introduction
9.2 Hospitals & Clinics
9.3 Research & Academic Institutes
9.4 Others
10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 Trend Analysis
10.2.2 North America Antimicrobial Resistance Surveillance Market by Country
10.2.3 North America Antimicrobial Resistance Surveillance Market by Solution
10.2.4 North America Antimicrobial Resistance Surveillance Market by Application
10.2.5 North America Antimicrobial Resistance Surveillance Market by End User
10.2.6 USA
10.2.6.1 USA Antimicrobial Resistance Surveillance Market by Solution
10.2.6.2 USA Antimicrobial Resistance Surveillance Market by Application
10.2.6.3 USA Antimicrobial Resistance Surveillance Market by End User
10.2.7 Canada
10.2.7.1 Canada Antimicrobial Resistance Surveillance Market by Solution
10.2.7.2 Canada Antimicrobial Resistance Surveillance Market by Application
10.2.7.3 Canada Antimicrobial Resistance Surveillance Market by End User
10.2.8 Mexico
10.2.8.1 Mexico Antimicrobial Resistance Surveillance Market by Solution
10.2.8.2 Mexico Antimicrobial Resistance Surveillance Market by Application
10.2.8.3 Mexico Antimicrobial Resistance Surveillance Market by End User
10.3 Europe
10.3.1 Trend Analysis
10.3.2 Eastern Europe
10.3.2.1 Eastern Europe Antimicrobial Resistance Surveillance Market by Country
10.3.2.2 Eastern Europe Antimicrobial Resistance Surveillance Market by Solution
10.3.2.3 Eastern Europe Antimicrobial Resistance Surveillance Market by Application
10.3.2.4 Eastern Europe Antimicrobial Resistance Surveillance Market by End User
10.3.2.5 Poland
10.3.2.5.1 Poland Antimicrobial Resistance Surveillance Market by Solution
10.3.2.5.2 Poland Antimicrobial Resistance Surveillance Market by Application
10.3.2.5.3 Poland Antimicrobial Resistance Surveillance Market by End User
10.3.2.6 Romania
10.3.2.6.1 Romania Antimicrobial Resistance Surveillance Market by Solution
10.3.2.6.2 Romania Antimicrobial Resistance Surveillance Market by Application
10.3.2.6.4 Romania Antimicrobial Resistance Surveillance Market by End User
10.3.2.7 Hungary
10.3.2.7.1 Hungary Antimicrobial Resistance Surveillance Market by Solution
10.3.2.7.2 Hungary Antimicrobial Resistance Surveillance Market by Application
10.3.2.7.3 Hungary Antimicrobial Resistance Surveillance Market by End User
10.3.2.8 Turkey
10.3.2.8.1 Turkey Antimicrobial Resistance Surveillance Market by Solution
10.3.2.8.2 Turkey Antimicrobial Resistance Surveillance Market by Application
10.3.2.8.3 Turkey Antimicrobial Resistance Surveillance Market by End User
10.3.2.9 Rest of Eastern Europe
10.3.2.9.1 Rest of Eastern Europe Antimicrobial Resistance Surveillance Market by Solution
10.3.2.9.2 Rest of Eastern Europe Antimicrobial Resistance Surveillance Market by Application
10.3.2.9.3 Rest of Eastern Europe Antimicrobial Resistance Surveillance Market by End User
10.3.3 Western Europe
10.3.3.1 Western Europe Antimicrobial Resistance Surveillance Market by Country
10.3.3.2 Western Europe Antimicrobial Resistance Surveillance Market by Solution
10.3.3.3 Western Europe Antimicrobial Resistance Surveillance Market by Application
10.3.3.4 Western Europe Antimicrobial Resistance Surveillance Market by End User
10.3.3.5 Germany
10.3.3.5.1 Germany Antimicrobial Resistance Surveillance Market by Solution
10.3.3.5.2 Germany Antimicrobial Resistance Surveillance Market by Application
10.3.3.5.3 Germany Antimicrobial Resistance Surveillance Market by End User
10.3.3.6 France
10.3.3.6.1 France Antimicrobial Resistance Surveillance Market by Solution
10.3.3.6.2 France Antimicrobial Resistance Surveillance Market by Application
10.3.3.6.3 France Antimicrobial Resistance Surveillance Market by End User
10.3.3.7 UK
10.3.3.7.1 UK Antimicrobial Resistance Surveillance Market by Solution
10.3.3.7.2 UK Antimicrobial Resistance Surveillance Market by Application
10.3.3.7.3 UK Antimicrobial Resistance Surveillance Market by End User
10.3.3.8 Italy
10.3.3.8.1 Italy Antimicrobial Resistance Surveillance Market by Solution
10.3.3.8.2 Italy Antimicrobial Resistance Surveillance Market by Application
10.3.3.8.3 Italy Antimicrobial Resistance Surveillance Market by End User
10.3.3.9 Spain
10.3.3.9.1 Spain Antimicrobial Resistance Surveillance Market by Solution
10.3.3.9.2 Spain Antimicrobial Resistance Surveillance Market by Application
10.3.3.9.3 Spain Antimicrobial Resistance Surveillance Market by End User
10.3.3.10 Netherlands
10.3.3.10.1 Netherlands Antimicrobial Resistance Surveillance Market by Solution
10.3.3.10.2 Netherlands Antimicrobial Resistance Surveillance Market by Application
10.3.3.10.3 Netherlands Antimicrobial Resistance Surveillance Market by End User
10.3.3.11 Switzerland
10.3.3.11.1 Switzerland Antimicrobial Resistance Surveillance Market by Solution
10.3.3.11.2 Switzerland Antimicrobial Resistance Surveillance Market by Application
10.3.3.11.3 Switzerland Antimicrobial Resistance Surveillance Market by End User
10.3.3.12 Austria
10.3.3.12.1 Austria Antimicrobial Resistance Surveillance Market by Solution
10.3.3.12.2 Austria Antimicrobial Resistance Surveillance Market by Application
10.3.3.12.3 Austria Antimicrobial Resistance Surveillance Market by End User
10.3.3.13 Rest of Western Europe
10.3.3.13.1 Rest of Western Europe Antimicrobial Resistance Surveillance Market by Solution
10.3.3.13.2 Rest of Western Europe Antimicrobial Resistance Surveillance Market by Application
10.3.3.13.3 Rest of Western Europe Antimicrobial Resistance Surveillance Market by End User
10.4 Asia-Pacific
10.4.1 Trend Analysis
10.4.2 Asia-Pacific Antimicrobial Resistance Surveillance Market by Country
10.4.3 Asia-Pacific Antimicrobial Resistance Surveillance Market by Solution
10.4.4 Asia-Pacific Antimicrobial Resistance Surveillance Market by Application
10.4.5 Asia-Pacific Antimicrobial Resistance Surveillance Market by End User
10.4.6 China
10.4.6.1 China Antimicrobial Resistance Surveillance Market by Solution
10.4.6.2 China Antimicrobial Resistance Surveillance Market by Application
10.4.6.3 China Antimicrobial Resistance Surveillance Market by End User
10.4.7 India
10.4.7.1 India Antimicrobial Resistance Surveillance Market by Solution
10.4.7.2 India Antimicrobial Resistance Surveillance Market by Application
10.4.7.3 India Antimicrobial Resistance Surveillance Market by End User
10.4.8 Japan
10.4.8.1 Japan Antimicrobial Resistance Surveillance Market by Solution
10.4.8.2 Japan Antimicrobial Resistance Surveillance Market by Application
10.4.8.3 Japan Antimicrobial Resistance Surveillance Market by End User
10.4.9 South Korea
10.4.9.1 South Korea Antimicrobial Resistance Surveillance Market by Solution
10.4.9.2 South Korea Antimicrobial Resistance Surveillance Market by Application
10.4.9.3 South Korea Antimicrobial Resistance Surveillance Market by End User
10.4.10 Vietnam
10.4.10.1 Vietnam Antimicrobial Resistance Surveillance Market by Solution
10.4.10.2 Vietnam Antimicrobial Resistance Surveillance Market by Application
10.4.10.3 Vietnam Antimicrobial Resistance Surveillance Market by End User
10.4.11 Singapore
10.4.11.1 Singapore Antimicrobial Resistance Surveillance Market by Solution
10.4.11.2 Singapore Antimicrobial Resistance Surveillance Market by Application
10.4.11.3 Singapore Antimicrobial Resistance Surveillance Market by End User
10.4.12 Australia
10.4.12.1 Australia Antimicrobial Resistance Surveillance Market by Solution
10.4.12.2 Australia Antimicrobial Resistance Surveillance Market by Application
10.4.12.3 Australia Antimicrobial Resistance Surveillance Market by End User
10.4.13 Rest of Asia-Pacific
10.4.13.1 Rest of Asia-Pacific Antimicrobial Resistance Surveillance Market by Solution
10.4.13.2 Rest of Asia-Pacific Antimicrobial Resistance Surveillance Market by Application
10.4.13.3 Rest of Asia-Pacific Antimicrobial Resistance Surveillance Market by End User
10.5 Middle East & Africa
10.5.1 Trend Analysis
10.5.2 Middle East
10.5.2.1 Middle East Antimicrobial Resistance Surveillance Market by Country
10.5.2.2 Middle East Antimicrobial Resistance Surveillance Market by Solution
10.5.2.3 Middle East Antimicrobial Resistance Surveillance Market by Application
10.5.2.4 Middle East Antimicrobial Resistance Surveillance Market by End User
10.5.2.5 UAE
10.5.2.5.1 UAE Antimicrobial Resistance Surveillance Market by Solution
10.5.2.5.2 UAE Antimicrobial Resistance Surveillance Market by Application
10.5.2.5.3 UAE Antimicrobial Resistance Surveillance Market by End User
10.5.2.6 Egypt
10.5.2.6.1 Egypt Antimicrobial Resistance Surveillance Market by Solution
10.5.2.6.2 Egypt Antimicrobial Resistance Surveillance Market by Application
10.5.2.6.3 Egypt Antimicrobial Resistance Surveillance Market by End User
10.5.2.7 Saudi Arabia
10.5.2.7.1 Saudi Arabia Antimicrobial Resistance Surveillance Market by Solution
10.5.2.7.2 Saudi Arabia Antimicrobial Resistance Surveillance Market by Application
10.5.2.7.3 Saudi Arabia Antimicrobial Resistance Surveillance Market by End User
10.5.2.8 Qatar
10.5.2.8.1 Qatar Antimicrobial Resistance Surveillance Market by Solution
10.5.2.8.2 Qatar Antimicrobial Resistance Surveillance Market by Application
10.5.2.8.3 Qatar Antimicrobial Resistance Surveillance Market by End User
10.5.2.9 Rest of Middle East
10.5.2.9.1 Rest of Middle East Antimicrobial Resistance Surveillance Market by Solution
10.5.2.9.2 Rest of Middle East Antimicrobial Resistance Surveillance Market by Application
10.5.2.9.3 Rest of Middle East Antimicrobial Resistance Surveillance Market by End User
10.5.3 Africa
10.5.3.1 Africa Antimicrobial Resistance Surveillance Market by Country
10.5.3.2 Africa Antimicrobial Resistance Surveillance Market by Solution
10.5.3.3 Africa Antimicrobial Resistance Surveillance Market by Application
10.5.3.4 Africa Antimicrobial Resistance Surveillance Market by End User
10.5.3.5 Nigeria
10.5.3.5.1 Nigeria Antimicrobial Resistance Surveillance Market by Solution
10.5.3.5.2 Nigeria Antimicrobial Resistance Surveillance Market by Application
10.5.3.5.3 Nigeria Antimicrobial Resistance Surveillance Market by End User
10.5.3.6 South Africa
10.5.3.6.1 South Africa Antimicrobial Resistance Surveillance Market by Solution
10.5.3.6.2 South Africa Antimicrobial Resistance Surveillance Market by Application
10.5.3.6.3 South Africa Antimicrobial Resistance Surveillance Market by End User
10.5.3.7 Rest of Africa
10.5.3.7.1 Rest of Africa Antimicrobial Resistance Surveillance Market by Solution
10.5.3.7.2 Rest of Africa Antimicrobial Resistance Surveillance Market by Application
10.5.3.7.3 Rest of Africa Antimicrobial Resistance Surveillance Market by End User
10.6 Latin America
10.6.1 Trend Analysis
10.6.2 Latin America Antimicrobial Resistance Surveillance Market by country
10.6.3 Latin America Antimicrobial Resistance Surveillance Market by Solution
10.6.4 Latin America Antimicrobial Resistance Surveillance Market by Application
10.6.5 Latin America Antimicrobial Resistance Surveillance Market by End User
10.6.6 Brazil
10.6.6.1 Brazil Antimicrobial Resistance Surveillance Market by Solution
10.6.6.2 Brazil Antimicrobial Resistance Surveillance Market by Application
10.6.6.3 Brazil Antimicrobial Resistance Surveillance Market by End User
10.6.7 Argentina
10.6.7.1 Argentina Antimicrobial Resistance Surveillance Market by Solution
10.6.7.2 Argentina Antimicrobial Resistance Surveillance Market by Application
10.6.7.3 Argentina Antimicrobial Resistance Surveillance Market by End User
10.6.8 Colombia
10.6.8.1 Colombia Antimicrobial Resistance Surveillance Market by Solution
10.6.8.2 Colombia Antimicrobial Resistance Surveillance Market by Application
10.6.8.3 Colombia Antimicrobial Resistance Surveillance Market by End User
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Antimicrobial Resistance Surveillance Market by Solution
10.6.9.2 Rest of Latin America Antimicrobial Resistance Surveillance Market by Application
10.6.9.3 Rest of Latin America Antimicrobial Resistance Surveillance Market by End User
11. Company Profiles
11.1 Robert Bosch GmbH
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 The SNS View
11.2 Bausch+Ströbel Maschinefabrik Ilshofen GmbH+Co. KG
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 The SNS View
11.3 Gerresheimer
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 The SNS View
11.4 Marchesini Group S.p.A
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 The SNS View
11.5 I.M.A. Industria Macchine Automatiche SpA
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 The SNS View
11.6 Venia LLC
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 The SNS View
11.7 Romaco Group
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 The SNS View
11.8 ProMach, Inc.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 The SNS View
11.9 Accutek Pharmaceutical Equipment Companies, Inc.
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 The SNS View
11.10 Herma GmbH
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 The SNS View
12. Competitive Landscape
12.1 Competitive Benchmarking
12.2 Market Share Analysis
12.3 Recent Developments
12.3.1 Industry News
12.3.2 Company News
12.3.3 Mergers & Acquisitions
13. Use Case and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Solution
Diagnostic kits
Diagnostic systems
Surveillance software
Services
By Application
Clinical Diagnostics
Public Health Surveillance
Other Applications
By End User
Hospitals & Clinics
Research & Academic Institutes
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Serum-free Media Market size was estimated at USD 1.70 billion in 2023 and is expected to reach USD 4.76 billion by 2032 at a CAGR of 12.16% during the forecast period of 2024-2032.
The Microservices in Healthcare Market Size was valued at USD 344 million in 2023 and is expected to reach USD 1601.69 million by 2031 and grow at a CAGR of 21.2% over the forecast period 2024-2031.
The Oxygen Therapy Market Size was valued at USD 33.82 billion in 2023 and is expected to reach USD 61.08 billion by 2032 and grow at a CAGR of 6.79% over the forecast period 2024-2032.
The Positron Emission Tomography (PET) Market size was estimated at USD 2.6 billion in 2023 and is expected to reach USD 4.35 billion by 2032 with a growing CAGR of 5.9% during the forecast period of 2024-2032.
The Orthobiologics Market was valued USD 7.15 billion in 2023 anticipated to grow USD 11.59 billion by 2032 with compound annual growth rate of 5.55% over the forecast period 2024-2032.
The Dermal Fillers Market was valued at USD 5.05 billion in 2023 and is estimated to reach USD 10.26 billion by 2032 and grow at a CAGR of 8.2% over the forecast period of 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
